Autoimmune Encephalitis Panel

What is Autoimmune Encephalitis Panel, CSF test?

The Autoimmune Encephalitis Panel, CSF is a diagnostic test that analyzes cerebrospinal fluid (CSF) to detect antibodies associated with autoimmune encephalitis—a condition where the body’s immune system mistakenly attacks the brain.

This panel helps identify specific autoantibodies that cause inflammation in the brain, aiding in the diagnosis and management of autoimmune encephalitis.  Some the antibodies included in Autoimmune Encephalitis Panel are ANTI LG1 AB, ANTI GABA AB, ANTI NMDA AB, ANTI CASPAR 2 AB, ANTI AMPA 1 AB, AMPA 2 AB

Why consider Autoimmune Encephalitis Panel, CSF test?

• To diagnose autoimmune encephalitis when symptoms like confusion, seizures, memory loss, or psychiatric changes are present.
• To distinguish autoimmune encephalitis from infections, tumors, or other neurological disorders.
• To guide treatment decisions, including immunotherapy.
• To monitor disease progression or response to therapy.

Who should get tested for Autoimmune Encephalitis Panel, CSF test?

• Patients exhibiting unexplained neurological symptoms such as sudden memory loss, seizures, psychiatric symptoms, or altered consciousness.
• Individuals suspected of having autoimmune encephalitis based on clinical examination and other test results.
• Patients with suspected autoimmune or paraneoplastic neurological syndromes.
• Neurologists may recommend this test to confirm diagnosis and tailor treatment.

More Information about Autoimmune Encephalitis Panel, CSF test

OTHER NAMES: CSF autoimmune encephalitis antibody panel, Autoimmune encephalitis antibody test in cerebrospinal fluid, Autoimmune brain antibody panel (CSF), Neural antibody panel

Autoimmune encephalitis is a condition where the body’s immune system mistakenly attacks the brain, causing inflammation. This inflammation can lead to a variety of neurological and psychiatric symptoms, including confusion, memory problems, seizures, mood changes, and difficulty speaking or moving. Diagnosis often involves detecting specific antibodies in the blood or cerebrospinal fluid (CSF), brain imaging, and clinical evaluation. Early diagnosis and treatment are crucial for better outcomes.